Big Molecule Watch

AUGUST 25, 2023

Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.

Drug Pricing 40

Drug Pricing Biosimilars Insurance Coverage and Processing Labelling 40

Pharma in Brief

FEBRUARY 2, 2022

The feedback will inform a stakeholder session in spring 2022 and the Panel’s final report. In Canada, coverage for prescription drugs exists through an array of public and private drug plans. The Panel is seeking input from stakeholders on or before February 25, 2022 via an online questionnaire. Background. a formulary); and.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Diabetes 59

FDA Law Blog: Biosimilars

OCTOBER 29, 2023

Since that blog post, an important step forward was the decoupling of the coverage requirement from the FDA Birth Control Guide in the guidance provided by the Department to plans and issuers.

Insurance Coverage and Processing 45

Insurance Coverage and Processing Communication 45

PharmaShots

JUNE 28, 2023

The decrease in Enbrel sales for 2022 was primarily driven by unfavorable changes to estimated sales deductions, lower volume, and lower net selling prices. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. Enbrel biosimilars Gabionline.net Centerforbiosimilars.com 7.

Biosimilars 40

Biosimilars Insurance Coverage and Processing Dosage Compounding 40